Pegvaliase: First Global Approval

Markham, Anthony

doi:10.1007/s40259-018-0292-3

2018-07-18

PRE

Markham, Anthony *

DOI：10.1007/s40259-018-0292-3

原文链接

原文求助

摘要

En 中文

BioMarin Pharmaceutical is developing pegvaliase (PALYNZIQ (TM)) as a treatment for phenylketonuria, a genetic disorder caused by deficiency of phenylalanine hydroxylase which leads to neurotoxic accumulation of phenylalanine. Data from the phase III PRISM clinical trial program indicate treatment with pegvaliase is associated with sustained reductions in blood phenylalanine levels and sustained improvements in neurological sequelae in patients with phenylketonuria. Based on these positive results pegvaliase was recently approved in the US for adults with phenylketonuria who have uncontrolled blood phenylalanine concentrations on current treatment. This article summarizes the milestones in the development of pegvaliase leading to this first approval.

Keyword:

PHENYLKETONURIA

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Biodrugs

IF:

6.9

论文数:

1.6K

被引数:

3.5K

机构

springer nature

学者数:

108

论文数: 516

被引数: 0

引用论文

Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2018-05-01

141

OAAI

Thomas, Janet; Levy, Harvey; Amato, Stephen; Vockley, Jerry; Zori, Roberto; Dimmock, David; Harding, Cary O.; Bilder, Deborah A.; Weng, Haoling H.; Olbertz, Joy; Merilainen, Markus; Jiang, Joy; Larimore, Kevin; Gupta, Soumi; Gu, Zhonghua; Northrup, Hope

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

LANCET

IF88.5

2014-07-01

147

OAAI

Longo, Nicola; Harding, Cary O.; Burton, Barbara K.; Grange, Dorothy K.; Vockley, Jerry; Wasserstein, Melissa; Rice, Gregory M.; Dorenbaum, Alejandro; Neuenburg, Jutta K.; Musson, Donald G.; Gu, Zhonghua; Sile, Saba

Partial rescue of neuropathology in the murine model of PKU following administration of recombinant phenylalanine ammonia lyase (pegvaliase)

MOLECULAR GENETICS AND METABOLISM

IF3.5

2017-09-01

OAAI

Goldfinger, Marc; Zeile, William L.; Corado, Carley R.; O'Neill, Charles A.; Tsuruda, Laurie S.; Laipis, Philip J.; Cooper, Jonathan D.

SIMD statement on investigational new drugs for rare disease therapies

MOLECULAR GENETICS AND METABOLISM

IF3.5

2012-03-01

PREAI

Longo, Nicola